Novo Nordisk A/S (NONOF)

Market Cap	218.82B -41.7%
Revenue (ttm)	48.59B +6.4%
Net Income	16.10B +1.4%
EPS	3.62 +1.8%
Shares Out	n/a
PE Ratio	13.59
Forward PE	14.88
Dividend	1.66 (3.34%)
Ex-Dividend Date	Mar 28, 2025

Volume	n/a
Average Volume	294,660
Open	49.00
Previous Close	49.13
Day's Range	49.00 - 49.00
52-Week Range	40.25 - 93.83
Beta	0.40
RSI	41.68
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 69,505
• Stock Exchange: OTCMKTS
• Ticker Symbol: NONOF

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK